EpiCast Report: Supportive Care in Oncology - Epidemiology Forecast to 2026

EpiCast Report: Supportive Care in Oncology - Epidemiology Forecast to 2026

Summary

Cancer is a broad term for a group of diseases characterized by uncontrolled cell proliferation. Worldwide, it is estimated that 14 million new cases of cancer are diagnosed each year, and 30-50% of those cases are preventable (WHO, 2017). Cancer is the second leading cause of death worldwide, with more than eight million deaths caused by cancer in 2015 (WHO, 2017).

GlobalData epidemiologists provide the number of diagnosed incident cases of all cancer treated with chemotherapy and the number of diagnosed incident cases of chemotherapy-treated cancers that develop associated conditions (neutropenia, anemia, oral mucositis, nausea and vomiting, and cachexia). GlobalData epidemiologists also provide the number of diagnosed incident cases of prostate, breast, and lung cancers, and those that progress to bone metastasis. To forecast the diagnosed incident and the five-year diagnosed prevalent cases of all cancer in the 7MM, GlobalData epidemiologists selected reputable international cancer databases and nationally representative, population-based studies that provided the diagnosed incidence or relative survival rates for all cancer in the 7MM.

In 2016, there were 933,412 diagnosed incident cases of all cancer receiving chemotherapy treatment in men and women, ages 18 years and older, in the 7MM. Combination therapy was more common, with 75.8% of cases receiving chemotherapy in conjunction with surgery, radiation, or both. The remaining cases, 24.2%, received chemotherapy alone. Of those receiving chemotherapy, anemia and nausea and vomiting were the most common conditions resulting from the treatment. In 2016, there were 809,204 cases of chemotherapy-induced anemia and 746,730 cases of chemotherapy-induced nausea and vomiting in the 7MM.

Scope

- The Supportive Care in Oncology EpiCast Report provides an overview of the risk factors and global trends of supportive care in oncology in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 7MM: diagnosed incident cases of all cancer; five-year diagnosed prevalent cases of all cancer; diagnosed incident cases of all cancer treated with chemotherapy; diagnosed incident cases all cancer treated with chemotherapy with chemotherapy induced condition (neutropenia, anemia, oral mucositis, nausea and vomiting, and cachexia); diagnosed incident cases of prostate cancer (men ages 35 years and older); diagnosed incident cases of breast cancer (women ages 20 years and older); diagnosed incident cases of lung cancer (men and women ages 20 years and older); diagnosed incident cases of prostate, breast, and lung cancer that metastasize to bone.
- The supportive care in oncology epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Supportive Care in Oncology EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global oncology and chemotherapy treatment market.
- Quantify patient populations in the global oncology and chemotherapy treatment market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for chemotherapy induced conditions therapeutics in each of the markets covered.
- Understand magnitude of chemotherapy induced conditions.

. List of Tables 3
. List of Figures 3
Supportive Care Oncology: Executive Summary 4
. Related Reports 6
. Upcoming Reports 7
3 Epidemiology 8
3. Disease Background 8
3. Global and Historical Trends 8
3.3 Forecast Methodology 0
3.3. Sources 0
3.3. Forecast Assumptions and Methods 7
3.4 Epidemiological Forecast for Supportive Care in Oncology (06-06) 3
3.4. Diagnosed Incident Cases of All Cancer 3
3.4. Diagnosed Incident Cases of All Cancer Receiving Chemotherapy Treatment 3
3.4.3 Diagnosed Incident Cases of Chemotherapy-Induced Conditions 4
3.4.4 Diagnosed Incident Cases of Prostate Cancer 5
3.4.5 Diagnosed Incident Cases of Prostate Cancer That Develop Bone Metastasis 6
3.4.6 Diagnosed Incident Cases of Breast Cancer 7
3.4.7 Diagnosed Incident Cases of Breast Cancer That Develop Bone Metastasis 8
3.4.8 Diagnosed Incident Cases of Lung Cancer 9
3.4.9 Diagnosed Incident Cases of Lung Cancer That Develop Bone Metastasis 30
3.4.0 Five-Year Diagnosed Prevalent Cases of All Cancer 3
3.5 Discussion 3
3.5. Epidemiological Forecast Insight 3
3.5. Limitations of Analysis 33
3.5.3 Strengths of Analysis 33
4 Appendix 34
4. Bibliography 34
4. About the Authors 37
4.. Epidemiologists 37
4.. Reviewers 37
4..3 Global Director of Therapy Analysis and Epidemiology 38
4..4 Global Head and EVP of Healthcare Operations and Strategy 38
4.3 About GlobalData 39
4.4 Contact Us 39
4.5 Disclaimer 39

List Of Tables

1.1 List of Tables
Table 1: 7MM, Diagnosed Incident Cases of All Cancer, Men and Women, Ages 20 Years 23

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available